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The application of mesenchymal stem cells (MSCs) is rapidly expanding due to their unique 
properties in cell therapy, especially as the feeder layer in the ex-vivo expansion of immune 
cells. Also, Interleukin 2 (IL-2) is an essential human cytokine in the expansion of 
hematopoietic precursors and progenitors, i.e., NK cells and T cells, while there is no 
endogenous expression of IL-2 in MSCs. This study aimed to examine the potency of amniotic 
membrane (AM)-MSCs as the IL-2 secretory cells. IL-2-containing pCMV3-C-GFPspark 
shuttle vector was transformed in E.coli DH5-alpha. After cloning, the plasmid DNA was 
extracted and transfected in isolated AM-MSCs, by lipofectamine-2000. Then, the RNA and 
protein expression levels of exogenous IL-2 were evaluated 3 to 15 days after transfection, 
using ELISA and qRT-PCR. Fluorescent microscopy and flowcytometry assays were used for 
evaluating the GFP-positivity of transfected AM-MSCs, as IL-2 expression control. There was a 
significant increase in RNA expression of exogenous IL-2 in transfected AM-MSCs in 3 to 15 
days after transfection. (p<0.001) Also, IL-2 concentration released in the medium was 
increased in 3rd day after transfection (611 pg/ml). However, the RNA and protein expression 
of IL-2 was reduced through passing the time. The results show AM-MSC is a suitable host for 
the expression and secretion of IL-2 as a critical cytokine in the ex-vivo expansion of 
hematopoietic precursors and progenitors, i.e., NK cells and T cells. Also, the survival time of 
IL-2 expression in AM-MSCs was long enough for use as a feeder layer. 
 





Cell therapy is a novel approach to cellular replacement or amplification aimed at tissue 
regeneration or restores lost functions [1]. Cellular immunotherapy is a high-tech medication 
